

Neeltje Steeghs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8612165/publications.pdf>

Version: 2024-02-01

89
papers

4,279
citations

257450

24
h-index

128289

60
g-index

91
all docs

91
docs citations

91
times ranked

6961
citing authors

#	ARTICLE	IF	CITATIONS
1	Healthy volunteers in first-in-human oncology drug development for small molecules. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1773-1784.	2.4	7
2	Effects of the Moderate CYP3A4 Inhibitor Erythromycin on the Pharmacokinetics of Palbociclib: A Randomized Crossover Trial in Patients With Breast Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 477-484.	4.7	4
3	Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. <i>Clinical Cancer Research</i> , 2022, 28, 1672-1679.	7.0	18
4	Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia. <i>Clinical Cancer Research</i> , 2022, 28, 870-881.	7.0	32
5	Plasma concentration guided dosing of drugs used for the treatment of childhood leukaemias: protocol for a systematic review. <i>BMJ Open</i> , 2022, 12, e053308.	1.9	0
6	Phase 2 study of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3 β) inhibitor, with gemcitabine/nab-paclitaxel (GnP) in first-line advanced pancreatic ductal adenocarcinoma (PDAC). <i>Journal of Clinical Oncology</i> , 2022, 40, 578-578.	1.6	0
7	Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03. <i>Journal of Clinical Oncology</i> , 2022, 40, 295-295.	1.6	17
8	Symptoms reported by gastrointestinal stromal tumour (GIST) patients on imatinib treatment: combining questionnaire and forum data. <i>Supportive Care in Cancer</i> , 2022, 30, 5137-5146.	2.2	3
9	Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib. <i>Pharmaceutical Research</i> , 2022, 39, 669-676.	3.5	6
10	Exposure-response analyses of cabozantinib in patients with metastatic renal cell cancer. <i>BMC Cancer</i> , 2022, 22, 228.	2.6	11
11	Evidence- and consensus-based guidelines for drug-drug interactions with anticancer drugs; A practical and universal tool for management. <i>Seminars in Oncology</i> , 2022, 49, 119-129.	2.2	10
12	Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature. <i>Cancers</i> , 2022, 14, 1832.	3.7	15
13	First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours. <i>British Journal of Cancer</i> , 2022, 126, 1010-1017.	6.4	8
14	Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer. <i>Drugs</i> , 2022, 82, 15-32.	10.9	3
15	Exposure-Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non-Small Cell Lung Cancer Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 394-402.	4.7	30
16	Therapeutic drug monitoring of oral targeted antineoplastic drugs. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 441-464.	1.9	110
17	Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer. <i>Oncologist</i> , 2021, 26, 290-e545.	3.7	21
18	Driver mutations occur frequently in metastases of well-differentiated small intestine neuroendocrine tumours. <i>Histopathology</i> , 2021, 78, 556-566.	2.9	11

#	ARTICLE	IF	CITATIONS
19	Updated results of European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 1202 cabazitaxel in patients with metastatic or inoperable locally advanced dedifferentiated liposarcoma.. Journal of Clinical Oncology, 2021, 39, 11518-11518.	1.6	2
20	Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors.. Journal of Clinical Oncology, 2021, 39, 3005-3005.	1.6	29
21	Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics. Cancer Medicine, 2021, 10, 4781-4789.	2.8	6
22	Location of Gastrointestinal Stromal Tumor (GIST) in the Stomach Predicts Tumor Mutation Profile and Drug Sensitivity. Clinical Cancer Research, 2021, 27, 5334-5342.	7.0	13
23	Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG â€œANITAâ€ European Journal of Cancer, 2021, 152, 26-40.	2.8	10
24	Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. European Journal of Surgical Oncology, 2021, 47, 2173-2181.	1.0	2
25	Response to â€œOptimized Alectinib Dose Regimen for Treatment of Patients With <i>ALK</i>â€Positive NSCLC Based on Robust Pharmacometric Analyses and Clinical Evidenceâ€ Clinical Pharmacology and Therapeutics, 2021, 110, 1164-1164.	4.7	2
26	A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs. Frontiers in Pharmacology, 2021, 12, 670862.	3.5	12
27	Precision Dosing of Targeted Therapies Is Ready for Prime Time. Clinical Cancer Research, 2021, 27, 6644-6652.	7.0	21
28	Evaluation of the Khorana, PROTECHT, and 5â€aâ€SNP scores for prediction of venous thromboembolism in patients with cancer. Journal of Thrombosis and Haemostasis, 2021, 19, 2974-2983.	3.8	14
29	Liquid Biopsies in Sarcoma Clinical Practice: Where Do We Stand?. Biomedicines, 2021, 9, 1315.	3.2	10
30	A phase II study on the neo-adjuvant combination of pazopanib and radiotherapy in patients with high-risk, localized soft tissue sarcoma. Acta Oncologica, 2021, 60, 1557-1564.	1.8	5
31	Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features. Nature Communications, 2021, 12, 574.	12.8	39
32	Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Nonâ€Small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 1256-1266.	7.0	20
33	Taste, smell and mouthfeel disturbances in patients with gastrointestinal stromal tumors treated with tyrosine-kinase inhibitors. Supportive Care in Cancer, 2021, , 1.	2.2	5
34	Early response evaluation using 18F-FDG-PET/CT does not influence management of patients with metastatic gastrointestinal stromal tumors (GIST) treated with palliative intent. Nuklearmedizin - NuclearMedicine, 2021, 60, 411-416.	0.7	1
35	Intra-Tumoral Pharmacokinetics of Pazopanib in Combination with Radiotherapy in Patients with Non-Metastatic Soft-Tissue Sarcoma. Cancers, 2021, 13, 5780.	3.7	2
36	Abstract LBA038: KontraSt: A Phase Ib/II, open-label, multi-center, dose-escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation. , 2021, , .		1

#	ARTICLE	IF	CITATIONS
37	Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol. <i>Cancers</i> , 2021, 13, 6281.	3.7	8
38	Imatinib, sunitinib and pazopanib: From flatâ€‘fixed dosing towards a pharmacokinetically guided personalized dose. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 258-273.	2.4	56
39	Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. <i>ESMO Open</i> , 2020, 5, e000787.	4.5	22
40	Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours â€‘ Results from daily clinical practice. <i>European Journal of Cancer</i> , 2020, 136, 140-148.	2.8	22
41	Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancer. <i>ESMO Open</i> , 2020, 5, e000619.	4.5	13
42	Pervasive chromosomal instability and karyotype order in tumour evolution. <i>Nature</i> , 2020, 587, 126-132.	27.8	221
43	PropAngio study protocol: a neoadjuvant trial on the efficacy of propranolol monotherapy in cutaneous angiosarcomaâ€‘a proof of principle study. <i>BMJ Open</i> , 2020, 10, e039449.	1.9	7
44	Neoadjuvant Systemic Treatment of Primary Angiosarcoma. <i>Cancers</i> , 2020, 12, 2251.	3.7	20
45	Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1075-1082.	1.9	8
46	RNA-Sequencing of Tumor-Educated Platelets, a Novel Biomarker for Blood-Based Sarcoma Diagnostics. <i>Cancers</i> , 2020, 12, 1372.	3.7	36
47	Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer. <i>British Journal of Cancer</i> , 2020, 122, 1166-1174.	6.4	30
48	Quality of treatment and surgical approach for rectal gastrointestinal stromal tumour (GIST) in a large European cohort. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1124-1130.	1.0	26
49	Cost-Neutral Optimization of Pazopanib Exposure by Splitting Intake Moments: A Prospective Pharmacokinetic Study in Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2020, 59, 941-948.	3.5	12
50	RNA-Sequencing of Tumor-Educated Platelets, A Novel Biomarker for Blood Based Sarcoma Diagnostics.. <i>European Journal of Surgical Oncology</i> , 2020, 46, e7.	1.0	4
51	Encorafenib, binimetinib and cetuximab combined therapy for patients with <i>BRAFV600E</i> mutant metastatic colorectal cancer. <i>Future Oncology</i> , 2020, 16, 161-173.	2.4	9
52	Pharmacokinetic Targets for Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Pediatric Oncology. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 494-505.	4.7	17
53	A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. <i>Nature Communications</i> , 2020, 11, 728.	12.8	140
54	Type of surgery in rectal gastrointestinal stromal tumour (GIST) does not affect outcome in a large european cohort. <i>European Journal of Surgical Oncology</i> , 2020, 46, e28.	1.0	0

#	ARTICLE	IF	CITATIONS
55	Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 917-930.	2.3	29
56	Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme. <i>European Journal of Cancer</i> , 2020, 130, 32-38.	2.8	11
57	Gastrointestinal Stromal Tumours (GIST) in Young Adult (18â€“40 Years) Patients: A Report from the Dutch GIST Registry. <i>Cancers</i> , 2020, 12, 730.	3.7	15
58	291â€¦Phase Ib study of selicrelumab (CD40 agonist) in combination with atezolizumab (anti-PD-L1) in patients with advanced solid tumors. , 2020, , .		6
59	Phase I study of afatinib plus selumetinib in patients with KRAS mutation-positive colorectal, non-small cell lung and pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3613-3613.	1.6	2
60	Encorafenib plus cetuximab with or without binimetinib for <i>BRAF</i> V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4001-4001.	1.6	35
61	Encorafenib plus cetuximab with or without binimetinib for <i>BRAF</i> V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4039-4039.	1.6	5
62	Encorafenib plus cetuximab with or without binimetinib for <i>BRAF</i> V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8-8.	1.6	25
63	Therapeutic drug monitoring of pazopanib: Using cost-neutral PK-guided interventions to optimize exposure.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3598-3598.	1.6	1
64	Activity of cabazitaxel in patients with metastatic or inoperable locally advanced dedifferentiated liposarcoma: European Organization for Research and Treatment of Cancer (EORTC) Phase II trial 1202.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11556-11556.	1.6	0
65	Therapeutic Drug Monitoring of Oral Anti-Hormonal Drugs in Oncology. <i>Clinical Pharmacokinetics</i> , 2019, 58, 299-308.	3.5	41
66	Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E-Mutated Colorectal Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 1632-1643.	27.0	918
67	The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. <i>Nature Genetics</i> , 2019, 51, 1450-1458.	21.4	250
68	Relevance of Endoxifen Concentrations: Absence of Evidence Is Not Evidence of Absence. <i>Journal of Clinical Oncology</i> , 2019, 37, 1980-1981.	1.6	18
69	Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1309-1318.	1.9	62
70	Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients. <i>Sarcoma</i> , 2019, 2019, 1-11.	1.3	1
71	Early Metabolic Response as a Predictor of Treatment Outcome in Patients With Metastatic Soft Tissue Sarcomas. <i>Anticancer Research</i> , 2019, 39, 1309-1316.	1.1	8
72	The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact. <i>Nature Communications</i> , 2019, 10, 5251.	12.8	130

#	ARTICLE	IF	CITATIONS
73	Oncological Outcome After Diagnostic Biopsies in Gastrointestinal Stromal Tumors. <i>Annals of Surgery</i> , 2019, Publish Ahead of Print, e1093-e1098.	4.2	7
74	Therapeutic Drug Monitoring of Oral Anticancer Drugs: The Dutch Pharmacology Oncology Group's Therapeutic Drug Monitoring Protocol for a Prospective Study. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 561-567.	2.0	33
75	The mutational footprints of cancer therapies. <i>Nature Genetics</i> , 2019, 51, 1732-1740.	21.4	212
76	Pan-cancer whole-genome analyses of metastatic solid tumours. <i>Nature</i> , 2019, 575, 210-216.	27.8	722
77	ALT-GIST: Randomized phase II trial of imatinib alternating with regorafenib versus imatinib alone for the first-line treatment of metastatic gastrointestinal stromal tumor (GIST). <i>Journal of Clinical Oncology</i> , 2019, 37, 11023-11023.	1.6	9
78	Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas. <i>Journal of Clinical Oncology</i> , 2019, 37, 2507-2507.	1.6	113
79	Concomitant intake of abiraterone and food to increase pharmacokinetic exposure: Real-life data from a therapeutic drug monitoring program. <i>Journal of Clinical Oncology</i> , 2019, 37, 3117-3117.	1.6	1
80	Boosting pazopanib exposure by splitting intake moments: A prospective pharmacokinetic study in cancer patients. <i>Journal of Clinical Oncology</i> , 2019, 37, 3119-3119.	1.6	3
81	Outcomes of advanced angiosarcoma and hemangioendothelioma on propranolol based regimens from sarcoma medical oncology clinic in North India. <i>Journal of Clinical Oncology</i> , 2019, 37, e22539-e22539.	1.6	2
82	Fast and Straightforward Method for the Quantification of Pazopanib in Human Plasma Using LC-MS/MS. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 230-236.	2.0	6
83	Outcome of Nonsurgical Management of Extra-Abdominal, Trunk, and Abdominal Wall Desmoid-Type Fibromatosis: A Population-Based Study in the Netherlands. <i>Sarcoma</i> , 2018, 2018, 1-8.	1.3	14
84	A single digital droplet PCR assay to detect multiple <i>KIT</i> exon 11 mutations in tumor and plasma from patients with gastrointestinal stromal tumors. <i>Oncotarget</i> , 2018, 9, 13870-13883.	1.8	28
85	Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing. <i>Clinical Pharmacokinetics</i> , 2017, 56, 987-997.	3.5	63
86	Elderly patients with gastrointestinal stromal tumour (GIST) receive less treatment irrespective of performance score or comorbidity – A retrospective multicentre study in a large cohort of GIST patients. <i>European Journal of Cancer</i> , 2017, 86, 318-325.	2.8	23
87	Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 765-776.	4.7	209
88	Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients. <i>Clinical Cancer Research</i> , 2016, 22, 5738-5746.	7.0	68
89	A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities. <i>Acta Oncologica</i> , 2015, 54, 1195-1201.	1.8	53